Daewoong Pharmaceutical Co.

Daewoong Pharmaceutical publica el mecanismo molecular de la bersiporocina como antifibrótico

by

-Daewoong Pharmaceutical publica el mecanismo molecular de la bersiporocina como antifibrótico en EMBO Molecular Medicine Elucidado el mecanismo molecular que subyace a la seguridad y eficacia de Bersiporocina La bersiporocina se encuentra actualmente en fase II de ensayo clínico para la fibrosis pulmonar idiopática SEÚL, Corea del Sur, 26 de mayo de 2023 /PRNewswire/ — Daewoong … Read more

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

by

Elucidated molecular mechanism behind safety and efficacy of Bersiporocin Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for … Read more

Daewoong Pharmaceutical veröffentlicht den molekularen Mechanismus von Bersiporocin als Antifibrotikum in der EMBO Molecular Medicine

by

Aufgeklärter molekularer Mechanismus hinter der Sicherheit und Wirksamkeit von Bersiporocin Bersiporocin befindet sich derzeit in einer klinischen Studie der Phase II zur Behandlung der idiopathischen Lungenfibrose SEOUL, Südkorea, 26. Mai 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae und Jeon Sengho) gab am 25. Mai bekannt, dass der molekulare Mechanismus hinter der Sicherheit und Wirksamkeit … Read more

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

by

Elucidated molecular mechanism behind safety and efficacy of Bersiporocin Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for … Read more

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

by

–  New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing erosive esophagitis (EE) regardless of food intake, and in a Chinese pivotal clinical trial program for the treatment of EE SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the … Read more